• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidones

Introduction to 3-sec-Butyl-6-methyluracil (CAS No: 6589-36-2)

3-sec-Butyl-6-methyluracil, identified by its Chemical Abstracts Service (CAS) number 6589-36-2, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This heterocyclic organic molecule belongs to the uracil derivatives, which have garnered considerable attention due to their diverse biological activities and potential applications in drug development. The structural uniqueness of 3-sec-butyl-6-methyluracil lies in its substitution pattern, where a sec-butyl group is attached at the C3 position and a methyl group at the C6 position of the uracil core. Such modifications contribute to its distinct chemical properties and biological functions, making it a subject of intense research interest.

The compound’s chemical structure consists of a pyrimidine ring system, which is a common motif in many biologically active molecules. The presence of the sec-butyl and methyl groups not only influences its physicochemical properties but also enhances its interactions with biological targets. This structural framework allows 3-sec-butyl-6-methyluracil to exhibit potential pharmacological effects, particularly in modulating enzymatic and receptor activities relevant to various diseases.

In recent years, 3-sec-butyl-6-methyluracil has been studied for its role in nucleic acid metabolism and as a potential scaffold for developing novel therapeutic agents. Uracil derivatives are known to interfere with DNA and RNA synthesis, making them candidates for anticancer and antiviral applications. The sec-butyl and methyl substitutions may enhance binding affinity to biological targets, improving the compound’s efficacy in inhibiting key enzymes involved in cellular processes.

One of the most compelling aspects of 3-sec-butyl-6-methyluracil is its potential as a lead compound in drug discovery. Researchers have explored its derivatives to develop molecules with enhanced pharmacokinetic profiles and reduced toxicity. For instance, modifications at the C3 and C6 positions have been shown to influence metabolic stability, solubility, and membrane permeability—critical factors for drug development.

Recent studies have highlighted the compound’s significance in preclinical models. In vitro experiments have demonstrated that 3-sec-butyl-6-methyluracil can modulate pathways associated with inflammation and oxidative stress, suggesting its therapeutic potential in conditions such as neurodegenerative diseases and chronic inflammation. Additionally, its ability to interact with nucleic acid bases has implications for gene therapy applications, where precise targeting of DNA or RNA is essential.

The synthesis of 3-sec-butyl-6-methyluracil involves multi-step organic reactions, often starting from commercially available uracil precursors. Advanced synthetic methodologies, including catalytic hydrogenation and nucleophilic substitution, have been employed to introduce the sec-butyl and methyl groups with high selectivity. These synthetic strategies are crucial for ensuring the purity and yield of the final product, which is critical for subsequent biological evaluations.

The pharmacological profile of 3-sec-butyl-6-methyluracil is still under extensive investigation. Preliminary data suggest that it may possess inhibitory effects on enzymes such as thymidylate synthase, which is pivotal in DNA biosynthesis. Such activity makes it a promising candidate for developing treatments against cancer and viral infections. Furthermore, its structural similarity to natural nucleobases allows it to potentially compete with endogenous bases during DNA replication, leading to chain termination or mutation.

In conclusion, 3-sec-butyl-6-methyluracil (CAS No: 6589-36-2) represents a fascinating molecule with significant potential in pharmaceutical research. Its unique structural features and demonstrated biological activities make it an invaluable asset in the quest for novel therapeutics. As research progresses, further elucidation of its mechanisms of action will likely uncover new avenues for treating various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)